These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35428720)

  • 1. Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis.
    Mease PJ; Kavanaugh A; Ogdie A; Wells AF; Bergman M; Gladman DD; Richter S; Teng L; Jardon S; Smolen JS
    J Rheumatol; 2022 Jul; 49(7):694-699. PubMed ID: 35428720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment-to-Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations.
    Mease PJ; Gladman DD; Ogdie A; Coates LC; Behrens F; Kavanaugh A; McInnes I; Queiro R; Guerette B; Brunori M; Teng L; Smolen JS
    Arthritis Care Res (Hoboken); 2020 Jun; 72(6):814-821. PubMed ID: 31909868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate achieves major cDAPSA response, and improvement in dactylitis and functional status in psoriatic arthritis.
    Appani SK; Devarasetti PK; Irlapati RVP; Rajasekhar L
    Rheumatology (Oxford); 2019 May; 58(5):869-873. PubMed ID: 30590763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients.
    Wells AF; Edwards CJ; Kivitz AJ; Bird P; Guerette B; Delev N; Paris M; Teng L; Aelion JA
    Rheumatology (Oxford); 2022 Mar; 61(3):1035-1043. PubMed ID: 34100922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study.
    Sfikakis PP; Vassilopoulos D; Katsifis G; Vosvotekas G; Dimitroulas T; Sidiropoulos P; Vounotrypidis P; Bogdanos DP; Georgountzos AΙ; Bounas AG; Georgiou P; Gazi S; Kataxaki E; Liossis SN; Theodorou E; Papagoras C; Theotikos E; Vlachoyiannopoulos P; Voulgari PV; Kekki A; Antonakopoulos N; Boumpas DT
    Rheumatol Int; 2023 May; 43(5):889-902. PubMed ID: 36856816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study.
    Ritchlin CT; Mease PJ; Boehncke WH; Tesser J; Chakravarty SD; Rampakakis E; Shawi M; Schiopu E; Merola JF; McInnes IB; Deodhar A
    Clin Rheumatol; 2024 Aug; 43(8):2551-2563. PubMed ID: 38844682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.
    Cutolo M; Myerson GE; Fleischmann RM; Lioté F; Díaz-González F; Van den Bosch F; Marzo-Ortega H; Feist E; Shah K; Hu C; Stevens RM; Poder A
    J Rheumatol; 2016 Sep; 43(9):1724-34. PubMed ID: 27422893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Apremilast to Achieve Psoriatic Arthritis Treatment Goals and Satisfaction at 1 Year in the Canadian Real-World APPRAISE Study.
    Chandran V; Bessette L; Thorne C; Sheriff M; Rahman P; Gladman DD; Anwar S; Jelley J; Gaudreau AJ; Chohan M; Sampalis JS
    Rheumatol Ther; 2024 Apr; 11(2):443-455. PubMed ID: 38416391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between methotrexate and apremilast in Psoriatic Arthritis-a single blind randomized controlled trial (APREMEPsA study).
    Samanta J; Naidu G; Chattopadhyay A; Basnet A; Narang T; Dhir V; Dogra S; Jain S; Sharma A
    Rheumatol Int; 2023 May; 43(5):841-848. PubMed ID: 36961603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE).
    Nash P; Ohson K; Walsh J; Delev N; Nguyen D; Teng L; Gómez-Reino JJ; Aelion JA;
    Ann Rheum Dis; 2018 May; 77(5):690-698. PubMed ID: 29343507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis.
    Kavanaugh A; Gladman DD; Edwards CJ; Schett G; Guerette B; Delev N; Teng L; Paris M; Mease PJ
    Arthritis Res Ther; 2019 May; 21(1):118. PubMed ID: 31077258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.
    Lubrano E; De Socio A; Perrotta FM
    J Rheumatol; 2017 Aug; 44(8):1159-1164. PubMed ID: 28572467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study.
    Coates LC; Gossec L; Zimmermann M; Shawi M; Rampakakis E; Shiff NJ; Kollmeier AP; Xu XL; Nash P; Mease PJ; Helliwell PS
    RMD Open; 2024 Mar; 10(1):. PubMed ID: 38531621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.
    Walsh JA; Gottlieb AB; Hoepken B; Nurminen T; Mease PJ
    Clin Rheumatol; 2018 Dec; 37(12):3285-3296. PubMed ID: 30191421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results.
    Smolen JS; Siebert S; Korotaeva TV; Selmi C; Bergmans P; Gremese E; Joven-Ibáñez B; Katsifis G; Noël W; Nurmohamed MT; Richette P; Sfikakis PP; de Vlam K; Theander E; Gossec L
    Ann Rheum Dis; 2021 Nov; 80(11):1419-1428. PubMed ID: 34162594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
    Edwards CJ; Blanco FJ; Crowley J; Birbara CA; Jaworski J; Aelion J; Stevens RM; Vessey A; Zhan X; Bird P
    Ann Rheum Dis; 2016 Jun; 75(6):1065-73. PubMed ID: 26792812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value.
    Coates LC; Gottlieb AB; Merola JF; Boone C; Szumski A; Chhabra A
    J Rheumatol; 2019 Feb; 46(2):160-165. PubMed ID: 30323006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
    Mease PJ; Young P; Fallon L; Mundayat R; Dina O; Blachley T; Middaugh N; Ogdie A
    Rheumatol Ther; 2024 Apr; 11(2):313-329. PubMed ID: 38252211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.
    Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Lespessailles E; Hall S; Hochfeld M; Hu C; Hough D; Stevens RM; Schett G
    Ann Rheum Dis; 2014 Jun; 73(6):1020-6. PubMed ID: 24595547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study.
    Mease PJ; Gladman DD; Deodhar A; McGonagle DG; Nash P; Boehncke WH; Gottlieb A; Xu XL; Xu S; Hsia EC; Karyekar CS; Helliwell PS
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32665433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.